Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Stock Has Average Price Target of $28.38

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has received a consensus recommendation of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $28.38.

A number of equities research analysts have recently commented on KMTS shares. Royal Bank Of Canada set a $30.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research report on Wednesday, July 15th. Piper Sandler reiterated an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company.

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS opened at $27.43 on Friday. The business has a fifty day moving average price of $25.83 and a 200-day moving average price of $23.05. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The company has a market capitalization of $1.63 billion, a PE ratio of -10.27 and a beta of 0.51. Kestra Medical Technologies has a 1-year low of $17.34 and a 1-year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The firm had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. As a group, equities analysts expect that Kestra Medical Technologies will post -2.45 EPS for the current fiscal year.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: BTIG issued a Buy rating on KMTS, adding to the constructive analyst outlook. The stock’s consensus price target is approximately $28.38, while BTIG has reportedly set a higher target of $32.00. Kestra Medical Technologies Gets a Buy from BTIG
• Positive Sentiment: Kestra received a five-star rating on Newsweek’s 2026 list of America’s Greatest Mid-Market Companies. It was the only medical equipment manufacturer among the honorees to receive the top rating, providing reputational support for its ASSURE wearable cardioverter defibrillator and broader cardiac-care platform. Kestra Medical Technologies Earns Five-Star Rating
• Neutral Sentiment: KMTS has been trading above its 50-day and 200-day moving averages and near its 52-week high, indicating strong recent momentum. Still, the consensus target of $28.38 suggests relatively limited upside at current levels. Kestra Medical Technologies Consensus Price Target
• Negative Sentiment: Director Raymond Cohen sold 3,330 shares worth about $97,500, reducing his holdings by 5.73%. The sale was disclosed as being used to cover tax withholding tied to vested equity awards, making it less concerning than a discretionary sale, although it adds to recent insider-selling pressure. Kestra Director Sells Shares
• Negative Sentiment: The company remains unprofitable: its latest quarterly loss missed analyst expectations, and analysts expect a full-year loss. That financial profile could restrain valuation despite improving commercial momentum.

Insider Activity at Kestra Medical Technologies

In related news, Director Elizabeth Kwo sold 4,010 shares of Kestra Medical Technologies stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $24.26, for a total value of $97,282.60. Following the completion of the sale, the director directly owned 14,116 shares in the company, valued at approximately $342,454.16. This trade represents a 22.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Conor Hanley sold 5,694 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $25.25, for a total value of $143,773.50. Following the completion of the transaction, the director directly owned 6,272 shares of the company’s stock, valued at approximately $158,368. This trade represents a 47.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 246,928 shares of company stock valued at $5,997,473 over the last three months. 5.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Brown Advisory Inc. grew its position in Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the period. Summit Partners Public Asset Management LLC purchased a new stake in Kestra Medical Technologies during the 4th quarter valued at $9,282,000. Next Century Growth Investors LLC lifted its holdings in shares of Kestra Medical Technologies by 154.5% during the 4th quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock valued at $12,354,000 after buying an additional 282,832 shares during the period. Eventide Asset Management LLC grew its holdings in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the period. Finally, Corient Private Wealth LP increased its position in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after acquiring an additional 44,839 shares during the last quarter.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies designed to help protect patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, or WCD, which is intended to provide temporary protection for patients who may be at elevated risk of life-threatening ventricular arrhythmias.

The ASSURE system continuously monitors a patient’s heart rhythm and is designed to detect potentially dangerous arrhythmias, including ventricular tachycardia and ventricular fibrillation.